For H1FY17, CSL Ltd Robust performance in H1FY17
Robust performance in H1FY17: For H1FY17, CSL Ltd (ASX: CSL) reported for a net profit after tax (NPAT) of $806 million, growth of $87 million or 12% on a reported basis against the prior comparable period (PCP). The underlying NPAT grew 36% and earnings per share (EPS) increased 39% on a constant currency (CC) basis (excluding the one-off items related to the Novartis influenza vaccines business acquisition). Based on the first half fiscal 2017 profit and expected performance for the second half of fiscal 2017, CSL has outlined NPAT growth for FY17 in the range of about 18% to 20% at constant currency over the FY16 result. The group along with an international team of scientists came up with a successfully prevention methodology for the progression of Diabetic Kidney Disease (DKD) in laboratory studies of type 2 diabetes. The stock has moved up 36.2% in last six months (as at June 08, 2017) and is trading near its 52-week elevated levels.
To read the complete report CLICK HERE. To get your free report CLICK HERE
Disclaimer DisclaimerThe advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people.Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376).The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation.Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product.The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd currently hold positions in: BHP, BKY, KCN, PDN, and RIO. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.CopyrightCopyright © 2015 Kalkine Pty Ltd ABN 34 154 808 312. No part of this website, or its content, may be reproduced in any form without the prior consent of Kalkine Pty Ltd.Kalkine is a trading name of Kalkine Pty Ltd ABN 34 154 808 312, which holds Australian Financial Services Licence No. 425376.